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With the current COVID-19 pandemic stretching South Africa (SA)’s 
already severely overburdened health system to its limits, the prompt 
diagnosis and urgent treatment of malaria with the most effective 
therapies has become even more critical. Untreated uncomplicated 
malaria, particularly infections caused by Plasmodium falciparum 
in non-immune individuals, rapidly progresses to severe disease 
(requiring intensive care) and often death. As fever is the primary 
symptom used for the screening of both malaria and COVID-19 
in SA, it is essential that healthcare workers maintain a high index 
of suspicion for malaria when a patient who lives in or has recently 
visited a malaria area presents with acute febrile illness. As SA enters 
the start of the malaria season (September to May), confirming or 
excluding a malaria infection when faced with such cases of acute 
febrile illness is now an imperative.
Signs and symptoms
Like those of many infectious diseases prevalent in Africa, the 
common early-stage clinical features of both malaria and COVID-19 
are nonspecific and include fever, headaches, fatigue and sore joints/
muscles. In areas where there is a high likelihood of co-infection, 
confirmatory tests for both diseases should be conducted as soon 
as possible to inform treatment. In the wake of the COVID-
19 pandemic, many healthcare professionals may attribute acute 
respiratory distress syndrome (ARDS) solely to severe COVID-19 
infection. However, it must be borne in mind that young children 
with malaria and patients with severe, complicated malaria often 
experience respiratory distress. This overlap in symptoms emphasises 
the importance of prompt testing for both diseases when patients 
living in malaria areas or who have recently travelled to a malaria 
risk area present with ARDS. Levels of certain biomarkers can assist 
with the differential diagnosis of these two diseases. COVID-19 
patients often present with lymphopenia,[1] while thrombocytopenia 
is common in malaria patients.[2,3] Although there have been recent 
reports of raised bilirubin levels in hospitalised patients with COVID-
19,[4,5] total bilirubin levels in malaria patients, particularly those with 
severe malaria, are significantly higher.[6,7] However, some other 
biochemical changes associated with COVID-19 are also shared with 
moderate to severe malaria, e.g. raised C-reactive protein[8,9] and 
transaminases.[7,10]
Point-of-care diagnosis
Unlike COVID-19, malaria has sensitive antigen-based point-of-care 
diagnostics that are readily available across the public and private 
healthcare sectors in SA. Malaria rapid diagnostic tests (RDTs) 
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As September marks the start of the malaria season in South Africa (SA), it is essential that healthcare professionals consider both COVID-
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malaria by either a rapid diagnostic test or microscopy enables prompt treatment with the effective antimalarial, artemether-lumefantrine, 
preventing progression to severe disease and death. Intravenous artesunate is the preferred treatment for severe malaria in both children and 
adults. Adding single low-dose primaquine to standard treatment is recommended in endemic areas to block onward transmission. Use of 
the highly effective artemisinin-based therapies should be limited to the treatment of confirmed malaria infections, as there is no clinical 
evidence that these antimalarials can prevent or treat COVID-19. Routine malaria case management services must be sustained, in spite of 
COVID-19, to treat malaria effectively and support SA’s malaria elimination efforts.
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generally produce a result within 20 minutes, enabling prompt 
treatment in the event of a positive test result or further investigation 
if the test is negative. As >90% of the malaria infections in SA 
are caused by P. falciparum, a falciparum-specific, histidine-rich 
protein  2 (HRP2)-based type of RDT is preferred. While HRP2-
based RDTs are highly sensitive, they must not be used for follow-up 
monitoring of treated malaria patients, as they could continue to give 
a positive result for up to 30 days after the patient has completely 
recovered from the disease, owing to persistent circulation of the 
HRP2. [11] For follow-up monitoring of a malaria patient, blood smear 
microscopy is the appropriate test. In line with recommendations 
from the World Health Organization (WHO), all patients should be 
followed up by microscopy on day 28 to confirm parasite clearance. 
Microscopic examination of blood smears is also required to quantify 
parasite density in order to diagnose hyperparasitaemia (>4% or 3+ 
parasitaemia), which should be treated as severe malaria.
Uncomplicated malaria
Despite an increasing prevalence of falciparum parasites resistant 
to the recommended antimalarial treatment, artemisinin-based 
combination therapies (ACTs), in the greater Mekong subregion 
of South-East Asia[12] and in Rwanda in Africa,[13] the ACT first 
introduced into KwaZulu-Natal Province in 2001,[14] artemether-
lumefantrine, remains highly efficacious in SA.[15] However, efficacy 
hinges on ensuring the correct dosage (Table 1), completion of the 
full treatment course, and ensuring that every dose is taken with at 
least 1.2 g of fat for optimal absorption of lumefantrine.[16] Currently 
in SA, artemether-lumefantrine, marketed as Coartem, is registered 
for use in patients weighing <65 kg, with the Coartem product 
information leaflet stating that ‘No adequate experience has been 
acquired in the use of Coartem® in patients weighing more than 
65 kg.’ As there have been suggestions that patients weighing >85 kg 
are more susceptible to treatment failure, it is critical to ensure full 
adherence and fat co-administration in this cohort of patients. For 
patients weighing >85 kg, extending the treatment course to FIVE 
days is advised, administering FOUR tablets per dose, given twice 
daily for a total of 10 doses (off-label recommendation).
In addition, it should be noted that some population groups that 
are often excluded from clinical trials, such as pregnant women and 
infants, those with comorbidities (e.g. malnutrition) and/or those 
taking concomitant medication (e.g. efavirenz, rifampicin), may be 
at increased risk of suboptimal antimalarial exposure and a poorer 
response to treatment.[17-20] Particularly careful attention should 
therefore be paid to ensuring their full adherence and monitoring 
their response to treatment. The use of oral quinine for the treatment 
of uncomplicated malaria is strongly discouraged, and it should only 
be used in patients allergic to artemether-lumefantrine.
While ACTs are primarily used to treat falciparum infections, 
they are highly effective against asexual blood stages of non-
falciparum species as well. Non-falciparum infections should be 
treated with artemether-lumefantrine as for falciparum infections 
(Table 1). A 14-day course of standard-dose primaquine phosphate 
(15 mg/d for adults or 0.25 - 0.5 mg base/kg/d) should follow 
artemether-lumefantrine treatment in children and adults with 
relapsing malaria (P. vivax or P. ovale), including mixed infections. 
However, primaquine should not be given to infants or to women 
who are pregnant and/or breastfeeding. Where available, glucose-6-
phosphate dehydrogenase (G6PD) status should guide administration 
of primaquine to prevent relapse. In individuals with confirmed 
G6PD deficiency, administration of primaquine base at 0.75 mg/
kg once a week for 8 weeks, with close medical supervision for 
potential primaquine-induced adverse haematological effects, is 
recommended.
Based on the gametocytocidal (transmission-blocking) properties 
of the antimalarial primaquine, the WHO recommended adding 
a single low dose of primaquine to ACTs to assist countries 
attempting to eliminate malaria as well as halt spread of artemisinin-
resistant parasites.[21] Unlike the higher doses and longer courses 
of primaquine required for the radical cure of P. vivax and P. ovale 
malaria, the single low dose of primaquine recommended for 
transmission blocking is not associated with severe haemolysis in 
G6PD-deficient individuals. [22] Following local data that confirmed 
the safety of single low-dose primaquine,[15] the South African Health 
Products Regulatory Authority approved its use under a section 21A 
application in selected health facilities in low-transmission malaria 
endemic districts to support malaria elimination efforts in SA.
Severe malaria
Patients with severe malaria present with a range of clinical signs 
and symptoms (Table 2). If one (or more) of these features is present, 
the patient should be treated promptly with intravenous (IV) or 
intramuscular artesunate (Garsun), the recommended treatment 
for severe malaria in SA. Injectable artesunate was registered for 
use in SA in June 2017, so section 21 approval for its use to treat 
severe malaria is no longer required. Treatment outcomes with IV 
artesunate compared with IV quinine are significantly better in 
both adults and children,[23] with fatality rates reduced by 39% in 
adults and 24% in children treated with IV artesunate as opposed 
to IV quinine.[24] In addition, IV artesunate is more cost-effective, 
has a simpler dosage regimen (Table 3), is easier to administer, has 
a better safety profile, and requires no dosage adjustment in renal 
or hepatic impairment.
Patients with severe malaria should receive at least three doses 
of IV artesunate (at 0, 12 and 24 hours), or the treatment should be 
continued until the patient is well enough to tolerate oral therapy, 
up to a maximum of 7 days with close monitoring for potential 
recrudescence. Once the patient is able to swallow, a complete full 
course (six doses) of artemether-lumefantrine as outlined in Table 1 
Table 1. Dosing schedule of artemether-lumefantrine
Body weight 
Time of dose and number of tablets
0 hours 8 - 12 hours 24 hours 36 hours 48 hours 60 hours
5 - <15 kg 1 tablet 1 tablet 1 tablet 1 tablet 1 tablet 1 tablet
15 - <25 kg 2 tablets 2 tablets 2 tablets 2 tablets 2 tablets 2 tablets
25 - <35 kg 3 tablets 3 tablets 3 tablets 3 tablets 3 tablets 3 tablets
35 - <65 kg 4 tablets 4 tablets 4 tablets 4 tablets 4 tablets 4 tablets
>65 kg* 4 tablets 4 tablets 4 tablets 4 tablets 4 tablets 4 tablets
*For patients weighing >85 kg, extend treatment course to FIVE days, administering FOUR tablets per dose, given twice daily for a total of 10 doses (off-label recommendation).
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must be administered. After IV artesunate, treatment-related delayed 
haemolysis may occasionally occur,[25] so haemoglobin values of 
recovering patients, particularly non-immune patients and those 
with high parasite densities, should be closely monitored for up to 
28 days.
Given the significant mortality reduction and cost-effective 
treatment advantages of IV artesunate,[23,24] the use of IV quinine for 
the treatment of severe malaria at any healthcare facility, public or 
private, is strongly discouraged. Denying patients access to life-saving 
IV artesunate while depleting existing stocks of IV quinine could be 
considered unethical. Use of IV quinine should only be considered 
if either the patient is allergic to artesunate or IV artesunate is not 
immediately available at the health facility. In the rare instances that 
IV quinine has to be administered, a loading dose (20 mg/kg body 
weight) must be given as a slow infusion (over 2 - 4 hours), followed 
by a maintenance dose (10 mg/kg body weight) 8 hours later. 
Treatment should be administered every 8 hours until the patient is 
able to tolerate oral medication.
Pregnant women
As malaria in pregnancy is associated with low-birthweight infants, a 
heightened risk of anaemia, and an increased risk of severe malaria, 
pregnancy loss and mortality in low-transmission areas,[26] it is 
critically important that malaria in pregnancy is treated as a medical 
emergency. For uncomplicated malaria, ACTs such as artemether-
lumefantrine are associated with significantly better treatment 
outcomes than quinine in all trimesters,[27] and are therefore the 
recommended treatment in SA.[28] Severe malaria in pregnancy 
should be preferentially treated with IV artesunate, as pregnant 
women are at significantly increased risk of quinine-associated 
hypoglycaemia.[29]
COVID-19 co-infection
Currently there are very limited data on treatment outcomes of 
malaria patients co-infected with COVID-19. In patients with a mild 
COVID-19 infection and uncomplicated malaria, we recommend 
that the standard weight-based six-dose artemether-lumefantrine 
treatment (Table 1) be administered, with the patient closely 
monitored to ensure complete parasite clearance. In critically ill 
patients, IV artesunate should be administered as soon as possible, 
with parasitaemia levels regularly monitored by microscopy to assess 
treatment response.
Chloroquine or hydroxychloroquine use should be limited to 
treatment of inflammatory autoimmune diseases such as systemic lupus 
erythematosus (SLE) and rheumatoid arthritis (RA).[30-32] Although 
initial in vitro data showed that hydroxychloroquine was capable of 
effectively inhibiting COVID-19,[33,34] these findings have not been 
replicated in in vivo clinical trial settings. The administration of 
hydroxychloroquine to patients with mild COVID-19 symptoms did 
not reduce viral load or the risk of hospitalisation, or shorten the 
time to complete resolution of symptoms, compared with individuals 
who received the standard-of-care treatment.[35] In patients with 
severe COVID-19, hydroxychloroquine administration did not affect 
intubation or in-hospital mortality rates,[36,37] and was associated with 
a prolonged QT interval.[38] In addition, the prophylactic effect of 
hydroxychloroquine against COVID-19 in individuals with SLE and 
RA has been shown to be negligible.[39] Although chloroquine was 
previously very effective against falciparum malaria and had a good 
safety profile,[40] the widespread entrenchment of chloroquine-resistant 
falciparum parasites rendered the antimalarial ineffective on the African 
continent and beyond,[41] necessitating its replacement with ACTs.
Because artemisinin and its derivatives have anti-inflammatory 
and immune regulatory properties,[42] there have been suggestions 
Table 2. Clinical and laboratory features of severe malaria
Impaired consciousness. A Glasgow Coma Score <11 in adults or a Blantyre Coma Score <3 in children
Prostration. Generalised weakness so that the person is unable to sit, stand or walk without assistance
Multiple convulsions. More than two episodes within 24 hours
Acidosis. A base deficit >8 mEq/L or, if not available, a plasma bicarbonate level <15 mmol/L or venous plasma lactate ≥5 mmol/L. Severe 
acidosis manifests clinically as respiratory distress (rapid, deep, laboured breathing)
Hypoglycaemia. Blood or plasma glucose <2.2 mmol/L (<40 mg/dL)
Severe anaemia. Haemoglobin concentration ≤5 g/dL or a haematocrit ≤15% in children <12 years of age; <7 g/dL and <20%, respectively, in 
adolescents and adults
Renal impairment. Plasma or serum creatinine >265 µmol/L (3 mg/dL) or blood urea >20 mmol/L
Jaundice. Plasma or serum bilirubin >50 µmol/L (3 mg/dL)
Pulmonary oedema. Radiologically confirmed or oxygen saturation <92% on room air with a respiratory rate >30/min, often with chest 
indrawing and crepitations on auscultation
Significant bleeding. Including recurrent or prolonged bleeding from the nose, gums or venepuncture sites; haematemesis, melaena, haematuria
Shock. Compensated shock is defined as capillary refill ≥3 seconds or temperature gradient on leg (mid- to proximal limb), but no hypotension. 
Decompensated shock is defined as systolic blood pressure <70 mm Hg in children or <80 mm Hg in adults, with evidence of impaired 
perfusion (cool peripheries or prolonged capillary refill)
Hyperparasitaemia. Plasmodium falciparum parasitaemia >4% or >3+
Table 3. Dosing schedule for intravenous artesunate
Body weight Dosing
Children <20 kg 3 mg/kg at 0, 12 and 24 hours then daily until patient is able to tolerate 
oral treatment, when full 6-dose 3-day artemether-lumefantrine treatment 
should be given
Adult and children ≥20 kg 2.4 mg/kg at 0, 12 and 24 hours then daily until patient is able to tolerate 
oral treatment, when full 6-dose 3-day artemether-lumefantrine treatment 
should be given
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that these drugs can be used to treat COVID-19 infections. However, 
at present there is no clinical evidence to support any use of 
artemisinin or any related herbal compounds in either the prevention 
or the treatment of COVID-19. Use of artemisinin and its derivatives 
must therefore be restricted to the treatment of malaria infections.
Conclusions
To ensure that the current COVID-19 pandemic does not result in a 
major upsurge in malaria cases, derailing SA’s elimination efforts, it 
is critical that the recommended malaria case management practices 
and procedures are closely adhered to by all healthcare practitioners. 
In addition, artemisinin-based therapies must be reserved for the 
treatment of malaria, as they are the only class of antimalarial still 
effective against falciparum malaria and have no proven effect in 
either preventing or treating COVID-19.
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